# US 2019/0376978 A1 · Biomarkers and methods for predicting preterm birth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376978 A1
- Document ID: US20190376978A1
- Status: Published application
- Kind: A1
- Application number: 16/255,757
- Filed: 2019-01-23
- Published: 2019-12-12
- Earliest claimed: 2013-03-15
- Assignees: Sera Prognostics, Inc.
- Applicants: Sera Prognostics, Inc.
- Inventors: Durlin Edward Hickok; John Jay Boniface; Gregory Charles Critchfield; Tracey Cristine Fleischer
- Web page: https://patentgrep.com/patent/US20190376978A1

## CPC

- G01N 33/689: {related to pregnancy or the gonads}
- C07K 4/12: from animals; from humans
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexpected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers.

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A method of determining probability for preterm birth in a pregnant female, the method comprising detecting a measurable feature of each of N biomarkers selected from the biomarkers listed in Tables 1 through 63 in a biological sample obtained from said pregnant female, and analyzing said measurable feature to determine the probability for preterm birth in said pregnant female.

### Claim 8 (depends on 7)

The method of claim 7, wherein said measurable feature comprises fragments or derivatives of each of said N biomarkers selected from the biomarkers listed in Tables 1 through 63.

### Claim 9 (depends on 7)

The method of claim 7, wherein said detecting a measurable feature comprises quantifying an amount of each of N biomarkers selected from the biomarkers listed in Tables 1 through 63, combinations or portions and/or derivatives thereof in a biological sample obtained from said pregnant female.

### Claim 10 (depends on 9)

The method of claim 9, further comprising calculating the probability for preterm birth in said pregnant female based on said quantified amount of each of N biomarkers selected from the biomarkers listed in Tables 1 through 63.

### Claim 11 (depends on 7)

The method of claim 7, further comprising an initial step of providing a biomarker panel comprising N of the biomarkers listed in Tables 1 through 63.

### Claim 12 (depends on 7)

The method of claim 7, further comprising an initial step of providing a biological sample from the pregnant female.

### Claim 13 (depends on 7)

The method of claim 7, further comprising communicating said probability to a health care provider.

### Claim 14 (depends on 13)

The method of claim 13, wherein said communication informs a subsequent treatment decision for said pregnant female.

### Claim 15 (depends on 7)

The method of claim 7, wherein N is a number selected from the group consisting of 2 to 24.

### Claim 16 (depends on 15)

The method of claim 15, wherein said N biomarkers comprise at least two of the isolated biomarkers selected from the group consisting of AFTECCVVASQLR, ELLESYIDGR, ITLPDFTGDLR, the biomarkers set forth in Table 50, and the biomarkers set forth in Table 52.

### Claim at position 12

17-23. (canceled)

### Claim 24 (depends on 7)

The method of claim 7, wherein said quantifying comprises mass spectrometry (MS).

### Claim 25 (depends on 24)

The method of claim 24, wherein said MS comprises liquid chromatography-mass spectrometry (LC-MS).

### Claim 26 (depends on 24)

The method of claim 24, wherein said MS comprises multiple reaction monitoring (MRM) or selected reaction monitoring (SRM).

### Claim 27 (depends on 26)

The method of claim 26, wherein said MRM (or SRM) comprises scheduled MRM (SRM).

### Claim 28 (depends on 7)

The method of claim 7, wherein said quantifying comprises an assay that utilizes a capture agent.

### Claim at position 18

29-65. (canceled)

### Claim 66

A method of predicting GAB, the method comprising: (a) quantifying in a biological sample obtained from said pregnant female an amount of each of N biomarkers selected from the biomarkers listed in Tables 1 through 63; (b) multiplying and/or thresholding said amount by a predetermined coefficient, (c) determining the predicted GAB birth in said pregnant female comprising adding said individual products to obtain a total risk score that corresponds to said predicted GAB.

### Claim 67

A method of predicting time to birth in a pregnant female, the method comprising: (a) obtaining a biological sample from said pregnant female; (b) quantifying an amount of each of N biomarkers selected from the biomarkers listed in Tables 1 through 63 in said biological sample; (c) multiplying and/or thresholding said amount by a predetermined coefficient, (d) determining predicted GAB in said pregnant female comprising adding said individual products to obtain a total risk score that corresponds to said predicted GAB; and (e) subtracting the estimated GA at time biological sample was obtained from the predicted GAB to predict time to birth in said pregnant female.

### Claim at position 21

68-79. (canceled)
